PTN — PALATIN TECHNOLOGIES INC

· Health Care · Pharmaceuticals · CIK 911216 ·
Last close
$14.44
Market Cap
$25.70M
52W High
$24.49
52W Low
$13.97
ADV30
16,028
Next earnings
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 3,920,675 -1,580,994 -1,432,987 13,225,337 10,159,494 2,633,459
Dec 2025 116,036 -7,328,548 -7,263,861 17,927,728 14,476,162 6,461,709
Sep 2025 8,847,550 4,661,053 4,677,534 8,614,660 1,273,083 8,218,261
Jun 2025 0 0 -4,602,654 -2,229,798 3,266,954 2,564,265 8,043,999

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,869,545
Investing CF
$3,130,000
Financing CF
$26,311,919
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-13.52
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-461,660,226
Inventory
Receivables
$1,636,325
ST Investments
EBIT TTM
$-9,619,763
Pretax Income TTM
$-9,627,545
Interest Exp TTM
$7,782
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$12,884,261
EBITDA
$-8,754,986
Free Cash Flow
Enterprise Value
$16,551,642
Total Cash
$10,159,494
Total Debt
$286,662
Shares Out
1,779,275
Trailing EPS
$0.11
Book Value
$6.53
ROE
-297.2%
ROA
-65.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025 0 -22,707,839 -17,307,349 3,266,954 8,043,999 -21,306,637
Jun 2024 4,490,090 -30,277,965 -29,736,113 10,742,266 10,853,763 -31,461,441
Jun 2023 4,853,678 -33,486,205 -24,036,741 17,939,440 19,919,311 -29,271,346
Jun 2022 1,468,457 -36,588,448 -36,198,299 36,070,794 19,802,919 -29,922,749

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.43

Peers — same industry

TickerNameMarket CapLastDaily %
CELU Celularity Inc $25.96M $0.90
NXTC NextCure, Inc. $25.36M $7.02
MDNAF Medicenna Therapeutics Corp. $26.14M $0.31
VTGN Vistagen Therapeutics, Inc. $25.23M $0.64
TPST Tempest Therapeutics, Inc. $26.21M $1.77

News headlines (Yahoo Finance, 1h cache)

Palatin to Begin Trading on Nasdaq Stock Exchange
2026-05-18 20:00 · Yahoo
Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ...
2026-05-13 23:03 · Yahoo
Transcript: Palatin Techs Q3 2026 Earnings Conference Call
2026-05-13 15:31 · Yahoo
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-05-13 11:30 · Yahoo
Palatin Technologies, Inc. Q2 2026 Earnings Call Summary
2026-02-18 13:30 · Yahoo
Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
2026-02-17 23:00 · Yahoo
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-02-17 12:30 · Yahoo
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
2025-11-12 17:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.